IL6 and Sepsis: This meta-analysis demonstrated that dexmedetomidine exerts a positive effect on reducing interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels in patients with sepsis, as well as lowering in-hospital mortality and 28-day mortality.